Arcutis to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
Arcutis Biotherapeutics (Nasdaq: ARQT) announced its participation in the Goldman Sachs 45th Annual Global Healthcare Conference from June 10-13, 2024. The event will feature a fireside chat on June 12 at 1:20 pm ET, accessible via webcast on the company's website. The replay will remain available for 180 days post-conference. Arcutis specializes in innovations in immuno-dermatology, aiming to provide significant advancements in this field.
- Participation in a high-profile event like the Goldman Sachs Global Healthcare Conference can increase visibility and attract potential investors.
- Webcast availability extends reach, allowing broader audience engagement and long-term access to the event's content.
- The press release lacks detailed financial updates or new product information, which may disappoint investors seeking substantial news.
WESTLAKE VILLAGE, Calif., June 03, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that Arcutis management will participate in the Goldman Sachs 45th Annual Global Healthcare Conference, taking place June 10-13, 2024.
Details for the company’s participation are as follows:
Fireside Chat Date: Wednesday, June 12, 2024
Fireside Chat Time: 1:20 pm ET
The webcast for this conference may be accessed at the “Events” section of the Company’s website. A replay of the webcast will be available on the Arcutis website for 180 days following the conference.
About Arcutis Biotherapeutics, Inc.
Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) is a commercial-stage medical dermatology company that champions meaningful innovation to address the urgent needs of individuals living with immune-mediated dermatological diseases and conditions. With a commitment to solving the most persistent patient challenges in dermatology, Arcutis has a growing portfolio including two FDA approved products that harness our unique dermatology development platform coupled with our dermatology expertise to build differentiated therapies against biologically validated targets. Arcutis’ dermatology development platform includes a robust pipeline with multiple clinical programs for a range of inflammatory dermatological conditions including scalp and body psoriasis, atopic dermatitis, and alopecia areata. For more information, visit http://www.arcutis.com or follow Arcutis on LinkedIn, Facebook, Instagram, and X.
Forward-Looking Statements
This press release and the anticipated fireside chat discussion contain “forward-looking” statements, including, among others, statements regarding Arcutis’ potential to address urgent needs and expectations with regard to the timing of data and regulatory events. These statements involve substantial known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements and you should not place undue reliance on our forward-looking statements. Risks and uncertainties that may cause our actual results to differ include risks inherent in the clinical development process and regulatory approval process, the timing of regulatory filings, the timing and expenses of commercialization efforts, and our ability to defend our intellectual property. For a further description of the risks and uncertainties applicable to our business, see the “Risk Factors” section of our Form 10-K filed with U.S. Securities and Exchange Commission (SEC) on February 27, 2024, as well as any subsequent filings with the SEC. You should not place undue reliance on any forward-looking statements in this press release. We undertake no obligation to revise or update information herein to reflect events or circumstances in the future, even if new information becomes available. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.
Contacts:
Media
Amanda Sheldon, Head of Corporate Communications
asheldon@arcutis.com
Investors
Latha Vairavan, Vice President, Finance and Investor Relations
lvairavan@arcutis.com
FAQ
When will Arcutis Biotherapeutics participate in the Goldman Sachs Healthcare Conference?
What time is Arcutis's fireside chat at the Goldman Sachs Healthcare Conference?
Where can I watch the Arcutis fireside chat from the Goldman Sachs Healthcare Conference?
What is the stock symbol for Arcutis Biotherapeutics?
